Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

lexatumumab

A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural ligand TRAIL, lexatumumab binds to and activates TRAIL-R2, which may trigger apoptosis in and inhibit the growth of TRAIL-R2-expressing tumor cells. TRAIL-R2, also known as death receptor 5 (DR5), is a member of the TNF receptor family and is expressed on many malignant cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-TRAIL receptor 2 monoclonal antibody HGS-ETR2
monoclonal antibody HGS-ETR2
Code name:HGS-ETR2
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search